ReviewJACC. CardioOncology2023
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies:
Review in JACC. CardioOncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Clinical Outcomes and Prognostic Implications of TAVR in Patients With Active Cancer: A Meta-Analysis.Clinical cardiology · 2025Pooled it
- Multimodality treatment and survival in primary cardiac malignancies: evidence from competing-risk and machine learning analyses.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- Transcatheter Aortic Valve Implantation in Cancer Patients: A Contemporary Review of the Specific Challenges, the Outcomes, Risk Stratification, and Decision-Making.Medicina (Kaunas, Lithuania) · 2026Review
- Patient-centered outcomes according to cancer status in cardiac surgery patients: a population-based cohort study.British journal of cancer · 2026Observational
- Review
- Current Perspectives in Cardio-oncology: Insights from Global Experts.European cardiology · 2026Article
- Predictive Factors of Unexpected Hospitalization within Six Months of Undergoing Percutaneous Coronary Intervention in Patients with Chronic Coronary Disease.Internal medicine (Tokyo, Japan) · 2025Article
- Lung Cancer and Cardiovascular Disease: Common Pathophysiology and Treatment-Emergent Toxicity.JACC. CardioOncology · 2025Review
- Short-Term Outcomes of Patients with Non-Metastatic Malignant Solid Tumor after Coronary Artery Bypass Grafting: A Population-Based Study of National/Nationwide Inpatient Sample From 2015 To 2020.Brazilian journal of cardiovascular surgery · 2025Article
- Taiwan Consensus for the Management of Cardiovascular Risks and Complications in Patients with Prostate Cancer.Acta Cardiologica Sinica · 2025Article
- Principles of optimal multidisciplinary management of prostate cancer in clinical practice.Cardio-oncology (London, England) · 2025Article
- Acute and Chronic Cardiovascular Adverse Events in Patients with Acute Myeloid Leukemia: A Systematic Review.Cancers · 2025Review
- Cardiovascular Risk in Prostate Cancer:JACC. CardioOncology · 2024Review
- Cardiovascular Considerations During Cancer Therapy: Gaps in Evidence andJACC. CardioOncology · 2024Review
- Outcomes of patients with active cancer after transcatheter aortic valve replacement: an updated meta-analysis.Cardio-oncology (London, England) · 2024Article
- Simultaneous surgical management of malignancy and coronary heart disease.Indian journal of thoracic and cardiovascular surgery · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Invasive cardiac interventions are recommended to treat ST-segment elevation myocardial infarction, non-ST-segment elevation acute coronary syndromes, multivessel coronary disease, severe symptomatic aortic stenosis, and cardiomyopathy. These recommendations are based on randomized controlled trials that historically included few individuals with active, advanced malignancies. Advanced malignancies represent a significant competing risk for mortality, and there is limited evidence to inform the risks and benefits of invasive cardiac interventions in affected patients. We review the benefit conferred by invasive cardiac interventions; the periprocedural considerations; the contemporary survival expectations of patients across several types of active, advanced malignancy; and the literature on cardiovascular interventions in these populations. Our objective is to develop a rational framework to guide clinical recommendations on the use of invasive cardiac interventions in patients with active, advanced cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.